Search

The article reports on the renewed interest in peptide drug market. It highlights the role of synthesis in helping the re-emergence and growth of the peptide ingredient market. Though peptides have been present for a long time, they only come into prominence later. The article sees the disappearance of a dichotomy among peptide manufacturers.

The article reports on the initiative of chemical firms to develop better peptide drug candidates. Their initiative aims to expand the pharmaceutical class and attract big pharmaceutical partners. Under clinical development are about 149 peptide drug candidates. The firms mentioned include Eli Lilly & Co., Aileron Therapeutics, KAI Pharmaceuticals and AngioChem.

Reports on the plans of fine chemicals companies to take advantage of opportunities in the market for peptide therapeutics. Factors contributing to the growth of the peptide market; Valuation of the global peptide pharmaceutical market; Peptide drugs approaching commercialization. INSET: Special delivery..

The article discusses a case study in which the Ironwood Pharmaceuticals Inc. has developed several strategies for development of peptide drug. It highlights that advantage of the polypeptide drugs developed by the company which can be administered orally and are secure from the digestive action of enzymes present in gastrointestinal tract. The contractual agreement of the company with Polypeptide Laboratories Inc. and Corden Pharma company for manufacturing of peptide drug is also included.

The article discusses research by Gerard C. L. Wong and others of the University of California, Los Angeles, published in the journal "ACS Nano" in 2014, related to synthesis of a 12 amino acid peptide pentobra which attaches to an antibiotic tobramycin to kill bacteria including Escherichia coli.

The article reports on Massachusetts Institute of Technology (MIT) researchers' development of a continuous process to reduce the amount of time it takes to research and develop peptide drugs.

Information about several papers discussed at the annual meetings of the Swiss Academy of Sciences and the Swiss Chemical Society in Zurich, Switzerland is presented. These include polymer coating held in place with a metal chelator, a cyclized peptide-like molecule which can help cancer patients rebuild their immune systems, and a new structural scaffold inspired by the epothilones. The meeting featured Karl Gademann, Alexander Lederer, Davide Pozzi, and Fabian Feyen.

A letter to the editor is presented in response to the article "Changing Tides" in the July 17, 2006 issue.

This article reports that the Swiss custom manufacturing giant Lonza Inc., has paid $145 million for the purchase of UCB-Bioproducts, the peptide-drug-manufacturing arm of Brussels-based pharmaceutical company UCB. Due to this purchase, Lonza can gain a process development and peptide synthesis facility in Braine-l'Alleud, outside Brussels. According to UCB, the plant which will be used to contract manufacture of peptides, has the world's largest capacity. Lonza made this move to solidify its position in pharmaceutical custom manufacturing because other companies are reconsidering theft commitment to the industry due to a decline in demand and tougher competition especially from Asia.

Reports on the decision of scientists from Novozymes to isolate plectasin, an antimicrobial peptide found in a fungus. Effectiveness of plectasin in combating bacterial infections; Capabilities of antimicrobial peptides to fight infections.

Presents information on the prediction of Braine-l' Alleud, Belgium-based UCB-Bioproducts regarding the sales growth of peptide-based active pharmaceutical ingredients. Applications of peptide-based therapies; Reason behind the growth of peptide-based therapies.

Focuses on the agreement between chemical firms Bachem and Theratechnologies to develop a peptide drug manufacturing process.